BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York City. The conference is sponsored by BioCentury and Thomson Reuters, among others.

Stephen M. Simes, BioSante’s president & CEO, will speak on April 15, 2011 at 10:00 am EDT. He will provide an overview of the company, as well as an update on the LibiGel ® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simes’ remarks may be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BPAX&item_id=3847287. The webcast will be archived approximately one hour after the live event and will be available for one year.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.

Copyright Business Wire 2010